Business
Less than six months after cutting 20% of its employees, Vedanta Biosciences has again laid off staff. According to one affected staffer, half of the Cambridge, Massachusetts–based biotech’s workforce is being cut while most of the rest are furloughed.
FEATURED STORIES
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday.
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite antivaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Astellas Pharma and Sutro Biopharma inked a global collaboration and licensing deal to work to discover and develop novel immunostimulatory antibody-drug conjugates.
Arzeda, Cyrus Biotechnology and Outpace Bio, are teaming up to use machine learning and optimize protein folding and design efforts.
Another C-suite change at Zymeworks was announced Monday, with the appointment of Paul Moore, Ph.D. as chief scientific officer.
For the first time in two years, the European Association for the Study of the Liver’s International Liver Congress was back on-site with cutting-edge research in hepatology and other sectors.
Otsuka Pharmaceutical and Lundbeck announced positive Phase III clinical trial results Monday regarding brexpiprazole (Rexulti) as a treatment for agitation in patients with Alzheimer’s dementia.
Intellia Therapeutics and Regeneron Pharmaceuticals presented positive interim data from an ongoing Phase I trial of NTLA-2001 for transthyretin (ATTR) amyloidosis.
RedHill announced that it will lay off a third of its U.S. workforce in an effort to save money over the next year and a half.
The life science industry is growing rapidly, and many companies have announced expansions and job creation. Still, others have been forced to cut costs and slash jobs. For that and more, continue reading.
The Roche Accelerator is designed to help companies bridge the gap between idea and proof-of-concept. It is one of several incubators recently founded by Western companies.
There were multiple leadership changes in the biopharma industry, with several new chief executive officers tapped to guide companies through their next growth phases.